MX388593B - Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. - Google Patents

Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.

Info

Publication number
MX388593B
MX388593B MX2019001860A MX2019001860A MX388593B MX 388593 B MX388593 B MX 388593B MX 2019001860 A MX2019001860 A MX 2019001860A MX 2019001860 A MX2019001860 A MX 2019001860A MX 388593 B MX388593 B MX 388593B
Authority
MX
Mexico
Prior art keywords
regimen
ofatumumab
multiple sclerosis
methods
treatment
Prior art date
Application number
MX2019001860A
Other languages
English (en)
Other versions
MX2019001860A (es
Inventor
Weisskopf Algirdas Jonas Kakarieka
Erik Wallström
Joseph Michael Kahn
Praz Marina Savelieva
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019001860A publication Critical patent/MX2019001860A/es
Publication of MX388593B publication Critical patent/MX388593B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a regímenes de tratamiento para tratar la esclerosis múltiple (MS). Estos métodos utilizan la administración de ofatumumab, un anticuerpo monoclonal anti-CD20, al paciente durante un régimen de dosis de carga y un régimen de mantenimiento
MX2019001860A 2016-08-15 2017-08-11 Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab. MX388593B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (2)

Publication Number Publication Date
MX2019001860A MX2019001860A (es) 2019-07-08
MX388593B true MX388593B (es) 2025-03-20

Family

ID=59901554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001860A MX388593B (es) 2016-08-15 2017-08-11 Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.

Country Status (24)

Country Link
US (5) US11161909B2 (es)
EP (5) EP3497132B1 (es)
JP (2) JP6851391B2 (es)
KR (2) KR20190038914A (es)
CN (5) CN120053639A (es)
AU (2) AU2017311664C1 (es)
CA (2) CA3101514A1 (es)
CY (1) CY1123350T1 (es)
DE (1) DE202017007542U1 (es)
DK (2) DK3733712T3 (es)
ES (2) ES2954259T3 (es)
FI (1) FI3733712T3 (es)
HR (2) HRP20230894T1 (es)
HU (2) HUE051948T2 (es)
IL (4) IL302488B2 (es)
LT (2) LT3733712T (es)
MX (1) MX388593B (es)
PL (2) PL3733712T3 (es)
PT (2) PT3733712T (es)
RS (2) RS64541B1 (es)
RU (1) RU2749951C2 (es)
SI (2) SI3497132T1 (es)
TW (1) TWI752995B (es)
WO (1) WO2018033841A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202017007542U1 (de) * 2016-08-15 2022-07-19 Novartis Ag Behandlungsschemata zur Behandlung von Multipler Sklerose unter Verwendung von Ofatumumab
CN114375306A (zh) * 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
CN114401742B (zh) 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms
MX2022012600A (es) * 2020-04-09 2023-02-15 Novartis Ag Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
CA2401948A1 (en) 2000-03-30 2001-10-11 Amgen, Inc. Cd20/ige-receptor like molecules and uses thereof
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AR082436A1 (es) 2010-08-02 2012-12-05 Sanofi Aventis Us Llc Uso de teriflunomida para tratar la esclerosis multiple
JP2014506258A (ja) * 2011-01-10 2014-03-13 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規使用
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
JP6348492B2 (ja) * 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
SG11201608674UA (en) 2014-04-29 2016-11-29 Teva Pharma Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
DE202017007542U1 (de) 2016-08-15 2022-07-19 Novartis Ag Behandlungsschemata zur Behandlung von Multipler Sklerose unter Verwendung von Ofatumumab
CN114401742B (zh) 2019-09-11 2024-05-24 诺华股份有限公司 通过转换疗法治疗rms
CN114375306A (zh) 2019-09-11 2022-04-19 诺华股份有限公司 奥法木单抗治疗患者中除多发性硬化症以外病症的管理
MX2022012600A (es) 2020-04-09 2023-02-15 Novartis Ag Ofatumumab para el tratamiento de ms mientras se mantiene la igg en el suero.
WO2022219057A1 (en) 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
WO2023020802A1 (en) 2021-08-16 2023-02-23 Novartis Ag Ofatumumab for treating pediatric ms

Also Published As

Publication number Publication date
CA3030530A1 (en) 2018-02-22
CN120053639A (zh) 2025-05-30
JP7198786B2 (ja) 2023-01-04
EP4371611A2 (en) 2024-05-22
RS64541B1 (sr) 2023-09-29
US20240317878A1 (en) 2024-09-26
IL302488B2 (en) 2024-12-01
IL313932A (en) 2024-08-01
EP4252847A2 (en) 2023-10-04
ES2954259T3 (es) 2023-11-21
TWI752995B (zh) 2022-01-21
RU2019107146A (ru) 2020-09-15
HRP20201388T1 (hr) 2020-11-27
EP3733712A1 (en) 2020-11-04
JP2019511506A (ja) 2019-04-25
KR20200136503A (ko) 2020-12-07
CA3030530C (en) 2021-02-23
PL3497132T3 (pl) 2020-11-30
EP4711008A2 (en) 2026-03-18
IL276890B2 (en) 2023-10-01
AU2020201112A1 (en) 2020-03-05
US11161909B2 (en) 2021-11-02
RU2021105514A (ru) 2021-04-19
EP3497132B1 (en) 2020-06-24
PL3733712T3 (pl) 2023-10-16
CN120000782A (zh) 2025-05-16
HUE063625T2 (hu) 2024-01-28
FI3733712T3 (fi) 2023-08-22
IL302488B1 (en) 2024-08-01
DK3733712T3 (da) 2023-08-21
AU2020201112B2 (en) 2021-07-22
CY1123350T1 (el) 2021-12-31
LT3497132T (lt) 2020-10-12
CN120037367A (zh) 2025-05-27
JP6851391B2 (ja) 2021-03-31
IL276890B1 (en) 2023-06-01
EP4252847A3 (en) 2023-11-15
RU2019107146A3 (es) 2020-09-15
EP3733712B1 (en) 2023-05-24
DK3497132T3 (da) 2020-09-07
SI3733712T1 (sl) 2023-12-29
LT3733712T (lt) 2023-09-11
EP3497132A1 (en) 2019-06-19
PT3733712T (pt) 2023-08-31
US20240150485A1 (en) 2024-05-09
US20190177424A1 (en) 2019-06-13
JP2020100630A (ja) 2020-07-02
US20250289902A1 (en) 2025-09-18
HRP20230894T1 (hr) 2023-11-24
CA3101514A1 (en) 2018-02-22
US12570754B2 (en) 2026-03-10
US12338290B2 (en) 2025-06-24
HUE051948T2 (hu) 2021-03-29
SI3497132T1 (sl) 2020-10-30
US20220081488A1 (en) 2022-03-17
RS60807B1 (sr) 2020-10-30
AU2017311664B2 (en) 2020-01-02
ES2821924T3 (es) 2021-04-28
EP4371611A3 (en) 2024-07-24
CN120053638A (zh) 2025-05-30
IL264804B (en) 2020-09-30
IL302488A (en) 2023-06-01
WO2018033841A1 (en) 2018-02-22
AU2017311664C1 (en) 2025-05-22
TW201808333A (zh) 2018-03-16
AU2020201112C1 (en) 2025-05-22
RU2749951C2 (ru) 2021-06-21
IL276890A (en) 2020-10-29
RU2021105514A3 (es) 2022-02-08
CN109641965A (zh) 2019-04-16
DE202017007542U1 (de) 2022-07-19
MX2019001860A (es) 2019-07-08
KR20190038914A (ko) 2019-04-09
PT3497132T (pt) 2020-09-25
AU2017311664A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
ZA202005388B (en) Methods of treating ulcerative colitis
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX388593B (es) Regimenes y metodos de tratamiento de la esclerosis multiple usando ofatumumab.
MY209831A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
MX387283B (es) Tratamiento del cancer con tg02.
EA201792209A1 (ru) Схема введения пропущенных доз инъекционных сложных эфиров палиперидона длительного действия
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
BR112017014793A2 (pt) regime de dosagem para antagonistas de madcam
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
BR112017000556A2 (pt) terapia de combinação para câncer
MX2018002554A (es) Combinaciones de inhibidores de btk para tratar mieloma multiple.
SG10201810016XA (en) Methods of treating depression using nmda modulators
EA202193276A1 (ru) Способы лечения холангиокарциномы
ZA202108094B (en) Mirikizumab for use in a method of treating crohn's disease
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
MY207627A (en) Methods of treating psoriasis
MX2020005557A (es) Agonistas de fxr para el tratamiento de enfermedades hepaticas.
UA123994U (uk) Спосіб лікування поросят за гіпопластичної анемії
EA201791075A1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3×cd20
EA201991330A1 (ru) Способы лечения рака с помощью антител к tim-3